For Immediate Release
April 21, 2017
Get hold of
Paul F. Devine
Bellmawr, New Jersey, C.O. Truxton, Inc. is voluntarily recalling large amount 70952A of Phenobarbital Tablets, USP, 15 mg, to the buyer/user stage. The manufacturer received a confirmed customer criticism that a bottle labeled as phenobarbital 15 mg was uncovered to consist of phenobarbital 30 mg tablets.
This mislabeled item could expose the buyer or their pet(s) to prospective overdosing that can result in significant intoxication which may possibly lead to cardiogenic shock, renal failure, coma or death. C.O. Truxton, Inc. has not received any reviews of adverse functions relevant to this recall.
The item is indicated for use as a sedative or anticonvulsant and is packaged in a thousand count bottles, NDC 0463-6160-ten, UPC seven 0463616010 six, large amount selection 70952A, expiration day 11/seventeen. The 15 mg Tablet is debossed with “West-ward 445” on just one aspect and blank on the reverse aspect the 30 mg Tablet is debossed with “West-ward 450” on just one aspect and scored on the reverse aspect. The item was dispersed Nationwide in the United states to Physician & Veterinarian Procedure Facilities.
C.O. Truxton, Inc. is notifying all consumers on file who bought the influenced item by using US Mail which incorporates a recall letter, recall reaction type and is arranging for total credit score returns, replacements, and many others. of all recalled item. Customers/distributors/retailers that have recalled item really should end working with the item and return their item to their place of purchase.
Customers with thoughts pertaining to this recall can call C.O Truxton, Inc. by cellphone at (856) 933-2333, Monday to Friday concerning the hrs of 9am and 5pm (EST). Consumers really should call their medical doctor or healthcare supplier if they have knowledgeable any complications that may possibly be relevant to using or working with this drug item.
Adverse reactions or high-quality complications knowledgeable with the use of this item may possibly be reported to the Food and drug administration's MedWatch Adverse Party Reporting plan on line, by frequent mail or by fax.